Skip to main content

Genetic Technologies Settles IP Dispute with Genesis Genetics Institute

NEW YORK (GenomeWeb News) – Genetic Technologies today announced it has settled with Genesis Genetics Institute over GTG's patent covering its non-coding DNA technology.

GTG sued Detroit-based Genesis Genetics in September in US District Court Eastern District of Michigan, Southern Division, alleging Genesis Genetics infringed on US Patent No. 5,612,179 which was assigned by an entity called Genetype AG to GTG.

The patent is at the center of a number of lawsuits that GTG has leveled at competitors alleging infringement, and in July it settled with Reproductive Genetics Institute over similar litigation. That followed a deal between GTG and Bioscientia Institute for Medical Diagnostics in late June to settle a dispute over the '179 patent.

Terms of the settlement announced today were not disclosed.

On Friday, GTG said that New York has issued a Clinical Laboratory Permit to the firm, allowing it to offer its BREVAGen test to residents of the state.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.